依瑞奈尤单抗(Erenumab (Genetical Recombination)) - 药物靶点：CGRP receptor_在研适应症：偏头痛_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

erenumab、Erenumab (Genetical Recombination)、erenumab (r-INN)

+ [7]

靶点

CGRP receptor

作用方式

拮抗剂

作用机制

CGRP receptor 拮抗剂(降钙素基因相关肽-1型受体拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Novartis Pharmaceuticals Corp.Novartis Europharm Ltd.

+ [5]

非在研机构-

权益机构

Amgen, Inc.

Novartis AG

最高研发阶段批准上市

首次获批日期

美国 (2018-05-17),

偏头痛

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 10103843L

来源: *****

Sequence Code 10265161H

来源: *****

关联

67

项与依瑞奈尤单抗相关的临床试验

NCT06237062

/ TerminatedN/A

Real-world Experience of Patients Newly Started on Erenumab in the Gulf Region: a Longitudinal Prospective Observational Study

The objective of this study was to evaluate the effect of erenumab on medication-specific treatment satisfaction in patients who newly started on erenumab over 12 weeks

开始日期2024-06-05

申办/合作机构

Novartis Pharmaceuticals Canada, Inc.

NCT06212661

/ Enrolling by invitationN/AIIT

Migraine Medication Effects on Urinary Symptoms

A prospective observational cohort trial to study the effects of CGRP inhibitors (CGRPi) on lower urinary tract symptoms (LUTS) and bladder/pelvic pain. Candidates for either CGRPi or an alternative therapy for refractory migraines (OnabotulinumtoxinA (BoNTA) extracranial muscle injections) with baseline LUTS will be recruited. The investigators will assess LUTS and pelvic pain using validated symptom and quality-of-life questionnaires, pretreatment and at 3 months post-treatment follow-up, comparing change in symptoms based on treatment received.

开始日期2024-04-05

申办/合作机构

The Cleveland Clinic Foundation

NCT05684692

/ Recruiting临床2期IIT

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

This is a placebo-controlled, multi-arm phase II platform screening trial designed to test the safety, pain responses, and pharmacodynamic activity of multiple experimental therapies simultaneously in participants with moderate-to-severe pain due to schwannomatosis (SWN).
This Master Study is being conducted as a platform that may allow participants with pain associated with schwannomatosis to receive a novel intervention throughout this study. Embedded within the Master Study are individual drug sub-studies:
* Investigational Drug Sub-Study A: Siltuximab
* Investigation Drug Sub-Study B: Erenumab-Aooe

开始日期2023-08-31

申办/合作机构

The Schwartz Center for Compassionate Healthcare

[+2]

100 项与依瑞奈尤单抗相关的临床结果

登录后查看更多信息

100 项与依瑞奈尤单抗相关的转化医学

登录后查看更多信息

100 项与依瑞奈尤单抗相关的专利（医药）

登录后查看更多信息

570

项与依瑞奈尤单抗相关的文献（医药）

2026-01-01·JOURNAL OF CUTANEOUS PATHOLOGY

Pyoderma Gangrenosum Associated With Iatrogenic Interleukin 17A Blockade: A Report of Two Cases and a Review of the Literature

Review

作者: Crowson, Neil ; Magro, Cynthia M. ; Kalomeris, Taylor ; Nuovo, Gerard

ABSTRACT:

Pyoderma gangrenosum (PG) is a rare necrotizing neutrophilic dermatosis driven by monokines and cytokines elaborated by monocytes and autoreactive T cells, respectively. Th1‐mediated autoimmune disorders and myeloproliferative disease are among the potential disease associations. More recently, certain medications were implicated, including TNF‐alpha inhibitors, rituximab, and IL‐17A inhibitors, such as secukinumab, where the development of PG is held to represent a cutaneous immune adverse effect. We present two patients who developed an autoinflammatory syndrome resembling PG in the setting of drug therapy with agents exhibiting an IL‐17A inhibitory effect. The drugs were erunumab in one and secukinumab in the other. One patient received the anti‐calcitonin gene‐related peptide targeted therapy, erenumab, for migraine prophylaxis. While this drug has not been previously implicated in the development of PG, it can cause IL‐17A blockade. The other patient was on secukinumab, a monoclonal antibody that selectively targets IL‐17A. We documented a microenvironment enriched in IL‐17A, emphasizing that the blockade impacts the functionality of the receptor as opposed to a quantitative reduction in IL‐17A production by T cells. Qualitative functional IL‐17A blockade could result in a paradoxical increase in IL‐23, a pro‐inflammatory cytokine that may contribute to the influx of neutrophils pathogenetically implicated in PG.

2025-12-01·EUROPEAN JOURNAL OF NEUROLOGY

Prescription of Monoclonal Antibodies Against Calcitonin Gene‐Related Peptide for the Prophylaxis of Migraine in Austria: A Retrospective, Longitudinal Analysis of Nationwide Insurance Data

Article

作者: Reichardt, Berthold ; Gall, Walter ; Wöber, Christian ; Zebenholzer, Karin ; Gleiss, Andreas

ABSTRACT:

Background:

Insurance data allow insights into dispensations of medications. This retrospective study over 49 months examined dispensations of monoclonal antibodies against calcitonin gene‐related peptide (CGRP‐mAbs).

Methods:

Using nationwide insurance data, we examined dispensations of erenumab, fremanezumab, or galcanezumab from September 1, 2018 to September 30, 2022. We examined the duration of treatment and breaks (Kaplan–Meier curves, medians, quartiles), persistence (proportion of days covered), and switches, acute medications, and other preventatives.

Results:

Of 8.8 million persons, 8934 were at least once dispensed a CGRP‐mAb (83.5% women, median age 45 years). Median individual follow‐up time was 710 days, median duration of treatment with any CGRP‐mAb was 297 days, 42.9% had CGRP‐mAbs for at least 1 year. Median duration of treatment with the first‐ever CGRP‐mAb was 327 days; 63.4% experienced a therapy break. Within 1 year after stopping, 53.5% resumed the same CGRP‐mAb, 16.9% another CGRP‐mAb, 29.6% did not resume any CGRP‐mAb; 13.7% started a second CGRP‐mAb and 1.7% a third. 22% definitively stopped therapy within their follow‐up. Dispensation of triptans decreased during and after therapy with CGRP‐mAbs; dispensation of other acute prescription medications was low without change. 11.4% had other preventatives before and 2.4% during CGRP‐mAb therapy. The proportion of days covered was 96%.

Conclusions:

In this nationwide study persistence with CGRP‐mAbs was excellent; dispensations of triptans and other preventatives decreased during CGRP‐mAb therapy. Therapy breaks were common, but the majority resumed CGRP‐mAbs, which indicates the need for long‐term prophylaxis.

2025-12-01·Annals of Clinical and Translational Neurology

Prophylactic Management of Vestibular Migraine: A Systematic Review

Review

作者: Aljuaid, Rimas Warid ; Morad, Ahmed Salah ; Khan, Tanveer Nidal ; Almohammed, Hussain Ali ; Al Zoabi, Bayan Mohammed Khair ; Pereira, Mable ; Gharawi, Lamyaa Mohammed ; Kushara, Kawthar Faisal ; Thalib, Husna Irfan ; Alsaygh, Shahad Jawdat ; Abuhulayqah, Shaima ; Bin Saddiq, Bushra Wadi

ABSTRACT:

Background:

Vestibular migraine (VM) is a neurological disorder characterized by episodic vertigo in patients with migraine, contributing to substantial functional impairment. Although VM is relatively common, a consensus on effective prophylactic treatments is lacking. This systematic review aimed to evaluate the efficacy and safety of pharmacological and adjunct non‐pharmacological interventions for VM management.

Methods:

The systematic review was conducted following the PRISMA 2020 guidelines. PubMed, Web of Science, and Google Scholar were searched from inception to April 2025. Randomized controlled trials or cohort (retrospective and prospective) studies assessing prophylactic pharmacological or adjunct non‐pharmacological management in adults diagnosed with VM were included. The risk of bias was evaluated using the Cochrane RoB 2 and MINORS tools.

Results:

Nine studies (three RCTs, six cohort studies; total n = 687) met the inclusion criteria. Beta‐blockers, particularly propranolol, and antiepileptics, such as topiramate, consistently reduced VM symptoms, as measured using validated scales (Dizziness Handicap Inventory, Vertigo Symptom Scale, and Vestibular Activities of Daily Living). Anti‐CGRP monoclonal antibodies (erenumab and galcanezumab) showed favorable efficacy and tolerability. By contrast, calcium channel blockers and antidepressants yielded inconsistent outcomes. Vestibular rehabilitation, when used as an adjunct therapy, demonstrated functional benefits. Reported adverse effects were generally mild and treatment specific. Substantial heterogeneity in treatment protocols, outcome assessments, and follow‐up intervals precluded meta‐analysis; therefore, findings were synthesized qualitatively.

Conclusion:

Moderate‐quality evidence supports the use of propranolol and topiramate as first‐line prophylactic treatments for VM. Emerging data suggest that anti‐CGRP agents may be beneficial for refractory cases. Larger, rigorously designed trials are necessary to establish standardized and individualized treatment protocols.

151

项与依瑞奈尤单抗相关的新闻（医药）

2026-01-07

·PMLiVE

Amgen agrees to lower prescription drug costs in deal with US government

Amgen has announced a deal with the US government that will lower the company’s prescription drug costs for US patients while reinforcing its commitment to US innovation. As part of the agreement, Amgen’s direct-to-patient programme, AmgenNow, will be expanded to include Aimovig (erenumab) and Amjevita (adalimumab). This will lower the prices of each drug by nearly 60% and 80% respectively compared to the current US list prices. Both drugs will be available at a discounted monthly price of $299. AmgenNow was launched by the company in October 2025, reducing the price of Repatha (evolocumab) for patients in the US to $239 per month, which is almost 60% below its current US list price. The programme is open to all eligible patients, including those who are uninsured, patients enrolled in high-deductible health plans or those who choose to pay for prescription drugs with cash or out of pocket. Amgen has invested over $40bn in R&D and manufacturing in the US over the past seven years. In 2025, Amgen announced a further $2.5bn investment in US manufacturing capital investments. This included expansions of $900m in Ohio and $1bn in North Carolina. The agreement means that US pharmaceutical tariffs on the company will be delayed for three years. Robert A Bradway, chairman and CEO of Amgen, commented: “We look forward to…[seeing] that this biopharmaceutical innovation is appropriately supported globally.”

引进/卖出上市批准生物类似药

2026-01-02

·百度百家

偏头痛的原因和治疗方法是什么

偏头痛是一种常见的神经系统疾病，其典型特征为反复发作的中重度头痛，多呈搏动性，常伴随恶心、呕吐及对光、声敏感。以下是关于偏头痛的成因与治疗方法的详细分析： ### 一、偏头痛的发病原因1. **遗传因素** 约60%的偏头痛患者有家族史。研究发现，特定基因（如CACNA1A、ATP1A2等）突变可能导致神经元兴奋性异常，引发皮质扩散性抑制（CSD）——一种与先兆症状相关的脑电活动异常。 2. **神经血管机制** 三叉神经血管系统异常激活是核心机制。当三叉神经末梢释放降钙素基因相关肽（CGRP）等物质时，会引起脑膜血管扩张和炎症反应，导致搏动性头痛。 3. **内分泌与激素影响** 雌激素水平波动与女性偏头痛高发密切相关。月经期、妊娠或绝经期激素变化可能诱发发作，约70%的女性患者报告月经期头痛加重。 4. **环境诱因** - **饮食**：酪胺（红酒、奶酪）、亚硝酸盐（加工肉类）、咖啡因过量或戒断 - **应激**：情绪压力、焦虑或放松后（"周末头痛"现象） - **感官刺激**：强光、噪音、特殊气味（如香水） - **睡眠紊乱**：失眠或睡眠过度 5. **其他疾病关联** 卵圆孔未闭、焦虑抑郁障碍、癫痫等疾病可能增加偏头痛风险。 ### 二、临床分类与症状特点1. **无先兆偏头痛**（占80%）持续4-72小时的单侧头痛，活动加重，伴至少一项：恶心/呕吐或畏光畏声。 2. **先兆偏头痛** 发作前20-60分钟出现可逆性神经症状： - 视觉先兆（闪光、锯齿状波纹） - 感觉异常（针刺感扩散） - 言语障碍先兆症状通常在头痛出现前消退。 3. **慢性偏头痛** 每月头痛≥15天且持续3个月以上，其中≥8天符合偏头痛特征。常由药物过度使用导致。 ### 三、阶梯式治疗方案#### （一）急性期治疗1. **非特异性药物** - **NSAIDs**：布洛芬（400-600mg）、萘普生（550mg）对轻中度发作有效 - **对乙酰氨基酚**：适用于妊娠期患者（不超过3g/天） 2. **特异性药物** - **曲坦类**：舒马曲坦（50-100mg口服/6mg皮下）、佐米曲坦（2.5-5mg），通过收缩脑血管和阻断CGRP发挥作用。禁用于心血管疾病患者。 - **CGRP受体拮抗剂**：乌布吉泮（ubrogepant）适用于曲坦无效者 3. **止吐辅助** 甲氧氯普胺（10mg）既可缓解恶心，又能促进镇痛药吸收。 #### （二）预防性治疗（适用于每月≥4次发作）1. **一线药物** - **β受体阻滞剂**：普萘洛尔（80-240mg/天）、美托洛尔 - **抗癫痫药**：托吡酯（25-100mg/天）、丙戊酸钠 - **钙通道阻滞剂**：氟桂利嗪（5-10mg/晚） 2. **生物制剂** - **抗CGRP单抗**：厄瑞努单抗（erenumab）每月70-140mg皮下注射，可降低发作频率50%以上 3. **非药物疗法** - **神经调控**：经皮眶上神经电刺激（CE认证设备） - **行为疗法**：认知行为治疗（CBT）、生物反馈训练 #### （三）特殊情况处理1. **月经性偏头痛** 短期预防：月经前2天至结束后3天使用萘普生（550mg bid）或雌激素贴剂。 2. **妊娠期管理** 对乙酰氨基酚为首选，严重发作可在孕中期谨慎使用阿片类。禁用NSAIDs（孕晚期）和曲坦类。 3. **药物过量性头痛** 逐步撤停过度使用的止痛药（如每月≥15天使用曲坦），换用预防性药物。 ### 四、生活方式管理1. **饮食调整** 保持规律进食，避免已知诱发食物。补充核黄素（400mg/天）和辅酶Q10（300mg/天）可能有益。 2. **睡眠节律** 固定就寝和起床时间，睡眠时长控制在7-8小时。 3. **压力控制** 每日20分钟正念冥想可使发作频率降低35%（临床试验证据）。 4. **运动处方** 每周3次40分钟中等强度有氧运动（如快走、游泳）可减少发作强度。 ### 五、新兴研究方向1. **双重作用机制药物** 如Lasmiditan（5-HT1F激动剂），无血管收缩作用，适合心血管风险患者。 2. **非侵入性神经刺激** 远程电神经调节（REN）设备可通过上肢刺激抑制三叉神经活性。 3. **肠道菌群干预** 初步研究发现偏头痛患者肠道菌群中普雷沃菌属增多，益生菌调节可能是未来方向。注：所有用药需在神经科医师指导下进行，个体化方案需综合考虑共病、药物相互作用等因素。慢性偏头痛患者建议建立头痛日记，记录发作特征与用药情况以优化治疗。

2026-01-01

·有驾

GPCR复合物：推动药物研发的新方向

> GPCR复合物的重要性 G蛋白偶联受体（GPCRs）是药物开发的重要靶点。已批准的药物中，近半数都以GPCR为作用对象。这些受体蛋白一旦与细胞外配体结合，就会触发细胞内信号反应。然而，传统靶向受体蛋白的方法正面临挑战。因为越来越多的证据表明，许多受体蛋白并非单独发挥作用，而是与多种受体相关蛋白一起形成复合物。这些复合物在功能、信号通路和定位上与单独的受体蛋白有所不同，为药物研发提供了新的可能。由于这些受体相关蛋白在不同组织和细胞中的差异表达，多蛋白受体复合物往往局限于特定的组织或细胞类型，这为开发精准调节受体功能的药物提供了机会。 > 受体复合物的构成 GPCR与受体相关蛋白形成复合物，从而影响信号传导和药物研发策略。例如，以MCR辅助蛋白（MRAPs）为例，它们对黑素皮质素受体（MCR）家族的调节作用展示了复合物的复杂性。MRAPs不仅影响MCR的细胞表面表达，还参与信号传导和内化过程。这些发现说明，在药物研发中需要考虑复合物的结构和其内部成分的相互作用。 > 受体复合物研究实例研究实例表明，复合物在信号传导中的角色因细胞类型、组织定位、发育阶段和疾病状态而异。以MCR和GABAB受体为例，GABAB受体与K+通道四聚结构域（KCTD）蛋白家族成员形成稳定的复合物，为信号传导功能的调节提供了更多的可能性。 > 抗体在药物研发中的应用抗体在药物研发中展现出高亲和力和选择性。以erenumab为例，它是一种针对降钙素受体样受体（CALCRL）与受体活性修饰蛋白1（RAMP1）复合物的单克隆抗体，用于偏头痛的预防性治疗。抗体能够靶向受体复合物的特定构象，且可稳定其活性状态。 > 小分子与多肽的角色小分子药物依赖于结构多样的化合物库和高通量筛选（HTS）技术来识别能够调控受体复合物的潜在化合物。多肽由于其特性不佳，在某些情况下可能作为小分子的替代方案，但他们的药代动力学特性需要进一步优化。 > CGRP与受体复合物在偏头痛治疗中，CGRP受体复合物至关重要。研究了CALCRL必须与RAMP1结合以形成功能性受体的过程，其中erenumab正是针对此复合物设计的。 > 临床前与临床研究进展在临床前和临床研究中，各种小分子拮抗剂如olcegepant和telcagepant表现出对偏头痛的缓解作用。这些分子化学结构各异，统称为“gepants”，它们通过阻止CGRP与CALCRL–RAMP1接口的结合来发挥作用。 > 受体复合物带来的机遇与挑战随着对受体复合物的理解不断加深，未来药物研发将更关注这些复合物。这带来了开发更为多元化和有效治疗方案的希望，为患者提供副作用更少的治疗选项。

100 项与依瑞奈尤单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	依瑞奈尤单抗	N02CD01	DB14039

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
偏头痛	美国	Amgen, Inc.	2018-05-17

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
神经痛	临床2期	美国	Amgen, Inc.	2022-05-31
三叉神经疾病	临床2期	美国	Amgen, Inc.	2022-05-31
三叉神经损伤	临床2期	美国	Amgen, Inc.	2022-05-31
三叉神经痛	临床2期	美国	Amgen, Inc.	2022-05-31
颞下颌关节障碍	临床2期	美国	Amgen, Inc.	2021-11-15
皮肤潮红	临床2期	丹麦	Novartis Pharmaceuticals Corp.	2020-06-09
玫瑰痤疮	临床2期	丹麦	Novartis Pharmaceuticals Corp.	2020-06-09
头痛	临床2期	丹麦	Novartis AG	2019-04-05
头痛	临床2期	丹麦	Amgen, Inc.	2019-04-05
脑震荡后综合征	临床2期	丹麦	Novartis AG	2019-04-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04098250 (CTgov)	临床2期	创伤后头痛	6	Erenumab (Erenumab)	遞範網鏇醖繭製鑰餘壓(艱餘網憲壓鹽鬱鬱鹽襯) = 憲齋窪獵糧觸鏇獵窪獵範顧鹽憲鬱膚網網齋鑰 (襯鹽獵願廠願製願夢網, 2.8) 更多	-	2025-10-23
				Placebo (Placebo)	遞範網鏇醖繭製鑰餘壓(艱餘網憲壓鹽鬱鬱鹽襯) = 築鑰壓衊鏇鑰選範醖網範顧鹽憲鬱膚網網齋鑰 (襯鹽獵願廠願製願夢網, 6.0) 更多
NCT04884763 (CTgov)	临床2期	颞下颌关节障碍	30	Erenumab-aooe (Arm A)	蓋窪淵繭網選遞艱繭廠(選遞鹹淵築窪醖簾衊憲) = 窪網構觸獵襯積鑰鑰壓網遞廠膚網壓淵醖窪餘 (鹹構蓋製襯願網壓願積, 繭夢製窪膚鑰鬱範夢築 ~ 壓顧顧鏇衊築艱鏇齋壓) 更多	-	2025-08-19
				Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments (Arm B)	蓋窪淵繭網選遞艱繭廠(選遞鹹淵築窪醖簾衊憲) = 壓願築窪獵醖艱積積鏇網遞廠膚網壓淵醖窪餘 (鹹構蓋製襯願網壓願積, 鑰壓壓窪鬱醖觸鑰構簾 ~ 鬱淵餘糧窪憲鏇夢淵糧) 更多
NCT03971071 (Pubmed \| Eur J Neurol)	临床4期	继发性头痛症	552	Erenumab 70 mg	鬱鹽襯獵積觸鑰襯遞網(鑰醖憲鹹艱醖鏇獵憲鏇) = No new safety concerns were identified (grade ≥ 3, 35 [6.3%]; serious, 17 [3.1%]; adverse events leading to treatment discontinuation, 5 [0.9%]) 範壓積鹽襯繭積窪簾襯 (觸積製糧選網鹽夢簾顧 )	积极	2025-08-01
				Erenumab 140 mg
NCT04970355 (CHERUB01, Pubmed \| JAMA Netw Open)	临床2期	丛集性头痛 CGRP	81	Erenumab	鹹糧蓋齋鏇窪網範顧淵(衊淵願鑰廠衊積築憲構) = 觸壓壓鹽餘壓鹹夢餘夢鹽餘壓夢簾獵製艱鏇構 (壓蓋齋蓋觸蓋淵蓋鬱蓋 )	不佳	2025-06-17
				Placebo	鹹糧蓋齋鏇窪網範顧淵(衊淵願鑰廠衊積築憲構) = 積餘願獵繭憲夢蓋簾糧鹽餘壓夢簾獵製艱鏇構 (壓蓋齋蓋觸蓋淵蓋鬱蓋 )
NCT04674020 \| NCT04603976 (REFORM study, Pubmed \| J Headache Pain)	临床4期	偏头痛 soluble urokinase-plasminogen activator receptor (suPAR)	623	Erenumab 140 mg	廠繭衊選選築構範淵餘(鹹廠糧鹹獵蓋艱艱遞廠): P-Value = 0.005	不佳	2025-04-24
				erenumab (Healthy Controls)
NCT04084314 (APOLLON, Pubmed \| J Headache Pain) 人工标引	临床4期	偏头痛	701	Erenumab 70 mg	鹽選糧鏇窪鏇構鑰膚製(夢製遞醖鬱廠願簾壓憲) = 4.1% of total cohort discontinued erenumab treatment during open-label treatment phase. Out of these, 65.5% (N = 19) were considered treatment-related. 艱顧鬱艱齋遞憲選簾選 (衊蓋獵鹹鬱網廠網簾蓋 )	积极	2024-09-25
				Erenumab 140 mg
NCT04825678 (CTgov)	临床4期	偏头痛	240	Erenumab (Erenumab QM: Continued SoC)	夢築製鏇襯醖築範夢蓋(窪夢選積遞醖鏇簾鑰願) = 顧繭遞襯鑰壓齋遞膚餘顧願餘蓋築鹽壓鏇顧顧 (壓窪遞鹽醖鬱廠鬱鏇鬱, 32.48) 更多	-	2024-09-19
				Erenumab (Erenumab QM: Discontinued SoC)	夢築製鏇襯醖築範夢蓋(窪夢選積遞醖鏇簾鑰願) = 鬱鏇憲積獵網艱觸鬱齋顧願餘蓋築鹽壓鏇顧顧 (壓窪遞鹽醖鬱廠鬱鏇鬱, 57.66) 更多
NCT03971071 (Pubmed \| JAMA Neurol) 人工标引	临床4期	偏头痛	620	Erenumab 70 mg	觸簾積蓋窪餘願廠憲繭(齋蓋夢憲範積鏇夢廠夢) = 鏇糧鬱膚餘壓繭願製獵糧齋觸淵範夢夢築夢膚 (鬱蓋鏇構獵齋壓醖衊壓 ) 更多	积极	2024-09-16
				Erenumab 140 mg	觸簾積蓋窪餘願廠憲繭(齋蓋夢憲範積鏇夢廠夢) = 鹽遞夢蓋築衊艱襯構製糧齋觸淵範夢夢築夢膚 (鬱蓋鏇構獵齋壓醖衊壓 ) 更多
NCT04252742 (EMBRACE, CTgov)	临床4期	偏头痛	512	Placebo	壓積憲鹹顧鏇獵廠鹹醖(膚衊鬱壓壓繭蓋衊餘餘) = 鑰憲鑰選製簾糧壓鹽淵窪積淵網窪獵衊選窪鹽 (繭選鏇鹹憲觸製憲衊衊, 1.26) 更多	-	2024-08-30
NCT04265755 (INTERROGATE, CTgov)	临床4期	偏头痛	1,406	Erenumab (Erenumab 70 mg/140 mg)	鏇鏇餘蓋衊選齋選襯鹽 = 襯獵廠壓顧鹽壓憲範衊壓鏇觸廠積範廠醖積淵 (窪醖鏇顧獵鹹淵鬱鏇顧, 願繭積鬱窪鹹廠廠鹹簾 ~ 製夢範餘範糧遞築鹽觸)	-	2024-06-07
				Erenumab (Erenumab 70 mg)	觸觸鬱選衊膚選鹹鹹鏇(遞蓋餘廠憲鏇夢襯糧簾) = 鏇鬱艱網廠壓憲鏇鹹製鹽網獵簾齋鏇窪鑰窪製 (願鹽齋繭積鏇壓鏇選範, 夢糧蓋蓋選鑰遞繭鏇獵 ~ 鹹願艱鏇構獵鏇淵繭構) 更多